Capricor Therapeutics Faces Legal Challenges Ahead
In recent developments concerning Capricor Therapeutics, Inc. (NASDAQ: CAPR), investors are urged to consider their legal standing as a class action lawsuit has been initiated. This comes after claims of alleged securities fraud were made, potentially impacting shareholders significantly.
Understanding the Class Action Lawsuit
The class action, spearheaded by Levi & Korsinsky, LLP, aims to recover losses for individuals who invested in Capricor between October 9, 2024, and July 10, 2025. The lawsuit is a response to what is claimed to be misleading information released by the company regarding its lead drug candidate, deramiocel.
The Allegations
Investors were reportedly led to believe in the efficacy of deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD). However, subsequent disclosures revealed critical information was withheld. Allegations suggest the defendants misrepresented Capricor's compliance with necessary regulatory requirements, directly affecting stock values.
Impact on Investors
On July 11, 2025, a stark revelation occurred when Capricor publicly announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) denying its Biologics License Application (BLA) for deramiocel. This news resulted in a steep decline in share price from $11.40 to $7.64, pinpointing the financial damage sustained by investors.
What Should Investors Do?
Investors who believe they have suffered losses during the defined period have until September 15, 2025, to make their voices heard in court. As participation does not require being a lead plaintiff, many affected individuals may find this an opportune time to join. Interested parties can connect with Levi & Korsinsky for guidance and further information.
No Financial Risk to Participate
One of the significant advantages of joining this class action is that there are no out-of-pocket expenses for class members. Compensation might be obtainable without the burden of legal fees, making it accessible and financially viable for many investors.
Levi & Korsinsky's Track Record
Levi & Korsinsky has established itself as a strong advocate for shareholders, securing hundreds of millions for clients over two decades. With a dedicated team of over 70 professionals, they have the expertise required to navigate complex securities litigation successfully, positioning themselves as one of the top firms in the United States.
Contact Information for Interested Parties
For investors looking to learn more, get in touch with Joseph E. Levi, Esq. at Levi & Korsinsky, LLP. He can be reached via email or by phone. Investors' inquiries are welcomed and encouraged as part of this extensive legal process. The firm's contact details include:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
Email: jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
Frequently Asked Questions
What is the deadline for investors to join the class action?
The deadline for investors to request lead plaintiff status in the class action is September 15, 2025.
Who can participate in the lawsuit?
Individuals who invested in Capricor Therapeutics during the specified period may be eligible to join the class action.
What were the claims against Capricor?
The lawsuit alleges that Capricor made misleading statements about its drug candidate, deramiocel, affecting its stock prices.
Is there a cost to participate in the class action?
No, investors may be entitled to compensation without any up-front fees or expenses.
How can investors get more information about the lawsuit?
Interested investors can contact Levi & Korsinsky for further details on participation and potential legal actions.
